Literature DB >> 30685442

Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: The Atherosclerosis Risk in Communities study.

Anum Saeed1, Wensheng Sun1, Anandita Agarwala2, Salim S Virani3, Vijay Nambi3, Josef Coresh4, Elizabeth Selvin4, Eric Boerwinkle5, Peter H Jones6, Christie M Ballantyne1, Ron C Hoogeveen7.   

Abstract

BACKGROUND AND AIMS: Diabetes increases risk for atherosclerotic cardiovascular disease (ASCVD). Current guidelines do not recommend measuring lipoprotein(a), another ASCVD risk factor, in these individuals. We examined the association of lipoprotein(a) levels with incident ASCVD events in persons with and without diabetes or prediabetes.
METHODS: Lipoprotein(a) and other ASCVD risk factors were measured at baseline (1996-1998) in the biracial Atherosclerosis Risk in Communities study; participants without prevalent ASCVD (coronary heart disease or stroke) were monitored ∼15 years for incident ASCVD events.
RESULTS: Of 9871 eligible participants (mean age 63 years; 5816 women; 2155 African Americans), 1543 had diabetes and 3615 had prediabetes. Cumulative ASCVD incidence rates (event/1000-person years) were higher in participants with diabetes (26%) or prediabetes (13%) than in nondiabetic individuals (10%, p < 0.001). When comparing highest to lowest lipoprotein(a) categories (≥50 mg/dL vs. ≤10 mg/dL), increasing lipoprotein(a) levels were significantly associated with increasing incident ASCVD events in Caucasian participants with prediabetes (hazard ratio [HR] = 1.35; 95% confidence interval [CI] 1.07-1.69); p = 0.03) and diabetes (HR = 1.42; 95% CI 1.10-1.84; p < 0.01), but not those with normal fasting blood glucose. Adding lipoprotein(a) to Pooled Cohort Equation variables improved risk prediction in persons with diabetes (Δ in area under the receiver operating characteristic curve [AUC] 0.0087, net reclassification index [NRI] 0.1761) and prediabetes (ΔAUC 0.0025, NRI 0.0938).
CONCLUSIONS: In this biracial cohort, elevated lipoprotein(a) levels in Caucasian individuals with diabetes or prediabetes were associated with further increased ASCVD risk. Adding lipoprotein(a) to traditional risk factors improved ASCVD risk prediction.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Cardiovascular risk; Diabetes; Lipoprotein(a); Prediabetes; Prevention

Mesh:

Substances:

Year:  2018        PMID: 30685442      PMCID: PMC6699162          DOI: 10.1016/j.atherosclerosis.2018.12.022

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  21 in total

Review 1.  Lipoprotein (a) measurements for clinical application.

Authors:  Santica M Marcovina; John J Albers
Journal:  J Lipid Res       Date:  2015-12-04       Impact factor: 5.922

2.  Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study.

Authors:  Gillian L Booth; Moira K Kapral; Kinwah Fung; Jack V Tu
Journal:  Lancet       Date:  2006-07-01       Impact factor: 79.321

3.  Diabetes mellitus, prediabetes, and incidence of subclinical myocardial damage.

Authors:  Elizabeth Selvin; Mariana Lazo; Yuan Chen; Lu Shen; Jonathan Rubin; John W McEvoy; Ron C Hoogeveen; A Richey Sharrett; Christie M Ballantyne; Josef Coresh
Journal:  Circulation       Date:  2014-08-22       Impact factor: 29.690

4.  2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.

Authors:  Alberico L Catapano; Ian Graham; Guy De Backer; Olov Wiklund; M John Chapman; Heinz Drexel; Arno W Hoes; Catriona S Jennings; Ulf Landmesser; Terje R Pedersen; Željko Reiner; Gabriele Riccardi; Marja-Riita Taskinen; Lale Tokgozoglu; W M Monique Verschuren; Charalambos Vlachopoulos; David A Wood; Jose Luis Zamorano; Marie-Therese Cooney
Journal:  Eur Heart J       Date:  2016-08-27       Impact factor: 29.983

5.  Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease.

Authors:  Sotirios Tsimikas; Emmanouil S Brilakis; Elizabeth R Miller; Joseph P McConnell; Ryan J Lennon; Kenneth S Kornman; Joseph L Witztum; Peter B Berger
Journal:  N Engl J Med       Date:  2005-07-07       Impact factor: 91.245

6.  National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report.

Authors:  Terry A Jacobson; Matthew K Ito; Kevin C Maki; Carl E Orringer; Harold E Bays; Peter H Jones; James M McKenney; Scott M Grundy; Edward A Gill; Robert A Wild; Don P Wilson; W Virgil Brown
Journal:  J Clin Lipidol       Date:  2015-04-07       Impact factor: 4.766

Review 7.  Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.

Authors:  Sebhat Erqou; Stephen Kaptoge; Philip L Perry; Emanuele Di Angelantonio; Alexander Thompson; Ian R White; Santica M Marcovina; Rory Collins; Simon G Thompson; John Danesh
Journal:  JAMA       Date:  2009-07-22       Impact factor: 56.272

8.  Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy.

Authors:  Daniel I Chasman; Dov Shiffman; Robert Y L Zee; Judy Z Louie; May M Luke; Charles M Rowland; Joseph J Catanese; Julie E Buring; James J Devlin; Paul M Ridker
Journal:  Atherosclerosis       Date:  2008-07-26       Impact factor: 5.162

9.  Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).

Authors:  Amit V Khera; Brendan M Everett; Michael P Caulfield; Feras M Hantash; Jay Wohlgemuth; Paul M Ridker; Samia Mora
Journal:  Circulation       Date:  2013-11-17       Impact factor: 29.690

10.  Genetic variants associated with Lp(a) lipoprotein level and coronary disease.

Authors:  Robert Clarke; John F Peden; Jemma C Hopewell; Theodosios Kyriakou; Anuj Goel; Simon C Heath; Sarah Parish; Simona Barlera; Maria Grazia Franzosi; Stephan Rust; Derrick Bennett; Angela Silveira; Anders Malarstig; Fiona R Green; Mark Lathrop; Bruna Gigante; Karin Leander; Ulf de Faire; Udo Seedorf; Anders Hamsten; Rory Collins; Hugh Watkins; Martin Farrall
Journal:  N Engl J Med       Date:  2009-12-24       Impact factor: 91.245

View more
  11 in total

Review 1.  Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapies-a Clinical Perspective.

Authors:  Xiaoming Jia; Jing Liu; Anurag Mehta; Christie M Ballantyne; Salim S Virani
Journal:  Cardiovasc Drugs Ther       Date:  2020-09-30       Impact factor: 3.727

2.  Association of C-peptide and lipoprotein(a) as two predictors with cardiometabolic biomarkers in patients with type 2 diabetes in KERCADR population-based study.

Authors:  Mohammad Reza Mahmoodi; Hamid Najafipour
Journal:  PLoS One       Date:  2022-05-24       Impact factor: 3.752

3.  Diabetes risk loci-associated pathways are shared across metabolic tissues.

Authors:  Gerard A Bouland; Joline W J Beulens; Joey Nap; Arno R van der Slik; Arnaud Zaldumbide; Leen M 't Hart; Roderick C Slieker
Journal:  BMC Genomics       Date:  2022-05-14       Impact factor: 4.547

4.  Relation of First and Total Recurrent Atherosclerotic Cardiovascular Disease Events to Increased Lipoprotein(a) Levels Among Statin Treated Adults With Cardiovascular Disease.

Authors:  Nathan D Wong; Yanglu Zhao; Jennifer Sung; Auris Browne
Journal:  Am J Cardiol       Date:  2021-01-14       Impact factor: 2.778

Review 5.  Beyond Lipoprotein(a) plasma measurements: Lipoprotein(a) and inflammation.

Authors:  Gissette Reyes-Soffer; Marit Westerterp
Journal:  Pharmacol Res       Date:  2021-05-23       Impact factor: 10.334

Review 6.  Molecular, Population, and Clinical Aspects of Lipoprotein(a): A Bridge Too Far?

Authors:  Natalie C Ward; Karam M Kostner; David R Sullivan; Paul Nestel; Gerald F Watts
Journal:  J Clin Med       Date:  2019-11-27       Impact factor: 4.241

7.  Serum lipoprotein (a) associates with a higher risk of reduced renal function: a prospective investigation.

Authors:  Liping Xuan; Tiange Wang; Huajie Dai; Bin Wang; Jiali Xiang; Shuangyuan Wang; Hong Lin; Mian Li; Zhiyun Zhao; Jieli Lu; Yuhong Chen; Yu Xu; Weiqing Wang; Min Xu; Yufang Bi; Guang Ning
Journal:  J Lipid Res       Date:  2020-07-23       Impact factor: 5.922

Review 8.  Lp(a) and the Risk for Cardiovascular Disease: Focus on the Lp(a) Paradox in Diabetes Mellitus.

Authors:  Karam M Kostner; Gerhard M Kostner
Journal:  Int J Mol Sci       Date:  2022-03-25       Impact factor: 5.923

Review 9.  Phenotyping the Prediabetic Population-A Closer Look at Intermediate Glucose Status and Cardiovascular Disease.

Authors:  Elena Barbu; Mihaela-Roxana Popescu; Andreea-Catarina Popescu; Serban-Mihai Balanescu
Journal:  Int J Mol Sci       Date:  2021-06-25       Impact factor: 5.923

Review 10.  Lipoprotein (a): Recent Updates on a Unique Lipoprotein.

Authors:  Anum Saeed; Sina Kinoush; Salim S Virani
Journal:  Curr Atheroscler Rep       Date:  2021-06-19       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.